However, the tumoricidal effects of anti-PD-1 and anti-PD-L1 antibodies are likely mediated by the direct blocking of inhibitory PD-1 signals in effector T cells, and PD-L1 expressed on tumor cells or tumor-infiltrating immune cells, respectively [123,124,125]. Here, PDCD1 is linked to neoplasm.